劇症肝不全に対する肝移植におけるアフェレシスの役割(<特集>劇症肝炎の治療をめぐって)

概要

論文の詳細を見る
Between September 1997 and July 2003, we have performed 95 cases of living donor liver transplantation (LDLTx), including 17 cases (17.9%) of fulminant hepatic failure. The survival rates of these 17 cases of fulminant hepatic failure at 1, 3 and 5 years are respectively 81.5%, 81.5% and 81.5%, and seems better by approximately 10% than the results of nation-wide survey, being 71.3%, 70.6% and 70.6% respectively. With regard to the apheresis therapies through pre and post LDLTx, CHDF/HDF was the modality most frequently applied. The expected functions of CHDF/HDF in preoperative application include the prevention of deterioration of hepatic encephalopathy, and the support of hepatic and renal insufficiency. In addition, CHDF/CHF in conjunction with plasma exchange worked effectively in supporting small-for-size graft cases.
日本アフェレシス学会の論文
2003-10-31